Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate

The glomerular filtration rate (GFR) is a critical indicator of kidney health, reflecting how well the kidneys filter blood. Changes in GFR can signal potential kidney impairment, necessitating accurate measurement methods to monitor kidney function effectively.Various molecules can serve as markers for GFR measurement, with the ideal marker meeting several specific criteria. It must freely filter at the glomerulus, avoid reabsorption or secretion by the renal tubules, remain unmetabolized, not...

Renal Failure: Dose Adjustments

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...

Renal Drug Excretion: Tubular Reabsorption

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...

Renal Drug Excretion: Overview

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

Renal Drug Excretion: Glomerular Filtration

Renal Drug Excretion: Glomerular Filtration

The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Timing and treatment strategies according to SCAI classification in cardiogenic shock.

European heart journal supplements : journal of the European Society of Cardiology·2023

Same author

Predicting target lesion failure following percutaneous coronary intervention through machine learning risk assessment models.

European heart journal. Digital health·2023

Same author

Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial.

JAMA cardiology·2023

Same author

Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO Trial.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2023

Same author

Preliminary results from the Polish multicenter registry on Impella in high-risk PCI and cardiogenic shock: Lessons learned and how to further improve outcomes.

Kardiologia polska·2023

Same author

Prognostic Impact of Prefrailty and Frailty in Women Undergoing TAVR: Insights From the WIN-TAVI Registry.

The Canadian journal of cardiology·2023

Search research articles

Related Experiment Video

Updated: Jun 26, 2026

Reproducible Arterial Denudation Injury by Infrarenal Abdominal Aortic Clamping in a Murine Model

Reproducible Arterial Denudation Injury by Infrarenal Abdominal Aortic Clamping in a Murine Model

Published on: November 24, 2016

Renal function and drug-eluting stent.

Carlo Briguori, Flavio Airoldi, Alaide Chieffo

International Journal of Cardiology

|January 17, 2009

Summary

This summary is machine-generated.

Patients with severe chronic kidney disease (CKD) face higher risks of major adverse cardiac events (MACE) after drug-eluting stent (DES) procedures. Severe CKD is a key indicator for adverse outcomes following DES implantation.

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Related Experiment Videos

Last Updated: Jun 26, 2026

Reproducible Arterial Denudation Injury by Infrarenal Abdominal Aortic Clamping in a Murine Model

Reproducible Arterial Denudation Injury by Infrarenal Abdominal Aortic Clamping in a Murine Model

Published on: November 24, 2016

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Area of Science:

Cardiology
Nephrology
Interventional Cardiology

Background:

Drug-eluting stents (DES) are widely used for coronary artery disease treatment.
Chronic kidney disease (CKD) is a growing public health concern.
The impact of renal function on cardiovascular outcomes after DES implantation requires further elucidation.

Purpose of the Study:

To investigate the association between renal function and clinical outcomes in patients undergoing DES implantation.
To identify whether severe CKD predicts adverse cardiac events in this patient population.

Main Methods:

Retrospective analysis of 2314 patients treated with DES.
Assessment of renal function using standard clinical parameters.
Follow-up at 24 months to evaluate major adverse cardiac events (MACE).

Main Results:

Patients with severe CKD exhibited a higher cumulative incidence of MACE at 24 months.
The composite endpoint of death and myocardial infarction was significantly elevated in patients with severe CKD.
Severe CKD was identified as a predictor of MACE post-DES implantation.

Conclusions:

Severe chronic kidney disease is a significant risk factor for major adverse cardiac events after drug-eluting stent implantation.
Risk stratification in patients with CKD undergoing DES procedures is crucial for optimizing clinical outcomes.
Further research should focus on tailored management strategies for CKD patients receiving DES.